Likewise, increased expression of miR-29b did also correlate with decreased expression levels of DNMT3A. To further study this phenomenon, the same group performed overexpression of miR-29b using a transferrin-conjugated nanoparticle delivery system for synthetic miR-29b in AML cell lines and primary patient specimens followed by treatment with decitabine [83]. The gene discussed is DNMT3A; the disease is acute myeloid leukemia.